Catalyst Event

Merck and Co Inc (MRK) · Other

From Akros U.S. Large Cap 500 Protective Allocation Monthly Index (A500PAM)

6/19/2026, 12:00:00 AM

OtherSentiment: Positive

FDA PDUFA target action date for KEYTRUDA in combination with Welireg for the treatment of patients with clear cell renal cell carcinoma (ccRCC), which was granted Priority Review, is scheduled. High importance is justified by the potential impact of a major regulatory approval.

Korean Translation

신세포암(ccRCC) 환자 치료를 위한 키트루다와 웰리렉 병용 요법에 대한 FDA의 우선 심사 지정 처방약 사용자 수수료법(PDUFA) 목표 조치일 예정됨. 주요 규제 승인 가능성으로 높은 시장 영향이 예상됨.

Related Recent Events

View Full Timeline